The Effects of Xalatan, Travatan and Lumigan on Skin Pigmentation Near the Eye

Completed · Phase 4

Conditions studied: Glaucoma, Application Site Pigmentation Changes

In brief

The purpose of this study is to study changes in skin color that may be caused by using one of the three eye medicines: Xalatan, Travatan or Lumigan.

Key facts

Study ID

NCT00705757

Run by

Summa Health System

People needed

89

Starts

2008-03-01

Expected to finish

2011-04-01

Last updated by the study team

2016-01-18

Who can join

Age: 30 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• patients recently diagnosed with primary open angle glaucoma or ocular hypertension
• Caucasian and African American ethnicities
• Male and Female
• Age 30 and above

You may not qualify if…

• A history of ocular medication use within the last 12 months
• Inflammatory/ allergic skin diseases or dermatitis
• presence of periocular hyperpigmented skin lesions
• Systemic pigmentation disorders
• Use of systemic drugs that can affect skin pigmentation
• Visitation of tanning salons, or use of self tanning products
• Pregnancy or patients planning to become pregnant in the near future

Where it is running

• Arlington Eye Physicians — Arlington Heights, Illinois, United States
• Summa Health System — Akron, Ohio, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.